Brief observationA Rare Hematological Adverse Event Induced by Bevacizumab: Severe Thrombocytopenia
Section snippets
Case Report
A 73-year-old man with a past history of diabetes, hypertension, and genitourinary tuberculosis, was diagnosed with stage IV colon carcinoma with synchronous liver metastasis. He received neo-adjuvant FOLFOX regimen (5-fluorouracil, leucovorin, and oxaliplatin) for 6 cycles, and subsequently underwent primary tumor resection and left liver lobectomy. Adjuvant FOLFOX was given for 6 cycles. At first evaluation, liver metastases were diagnosed, and the patient was started on irinotecan plus
Discussion
We describe a case of acute immune-mediated thrombocytopenia triggered by bevacizumab. Bevacizumab has mild hematological toxicities per se but has been shown to slightly increase hematological adverse events when combined with chemotherapy.1 Of note, thrombocytopenia did not seem to be dose-dependent during bevacizumab dose escalation from 3 mg/kg to 20 mg/kg in breast cancer patients.6 Recently, it has been suggested that bevacizumab could induce nonsevere and reversible thrombocytopenia.7 In
References (20)
- et al.
Haematologic toxicities associated with the addition of bevacizumab in cancer patients
Eur J Cancer
(2011) - et al.
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
Semin Oncol
(2003) - et al.
Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods
Blood
(2010) - et al.
Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients
Eur J Cancer
(2005) - et al.
Bevacizumab
Oncologist
(2010) - et al.
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis
JAMA
(2011) - et al.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
N Engl J Med
(2004) - et al.
Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis
Oncology
(2004) - et al.
Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report
Cancer Chemother Pharmacol
(2010) - et al.
Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database
Platelets
(2011 Nov 18)
Cited by (12)
Spontaneous bleeding in thrombocytopenia: Is it really spontaneous?
2018, Transfusion Clinique et BiologiqueCitation Excerpt :Thrombocytopenia defined as a platelet count below the lower limit of 150,000 platelets/μL blood can be caused by a variety of reasons, one of the foremost being immune thrombocytopenia, formerly known as idiopathic thrombocytopenic purpura (ITP) [1]. Thrombocytopenia can be an isolated disorder or develop secondary to or in association with drug treatments [1–5] or conditions such as viral or bacterial infections [1,6–8]. Whatever the etiology of thrombocytopenia, thrombocytopenic patients have an increased risk of bleeding, which can be fatal in rare cases [1,9,10].
Biotherapies in metastatic colorectal cancers in 2014
2014, Presse MedicaleDrug-induced thrombocytopenia in a patient with colorectal cancer: A case report
2023, Oncology LettersHematological adverse events in the management of glioblastoma
2022, Journal of Neuro-OncologySevere proteinuria during the administration of bevacizumab plus mFOLFOX6 in a colorectal cancer patient after kidney transplantation: A case report
2020, Journal of Pharmaceutical Health Care and Sciences
Funding: None.
Conflict of Interest: Dr Mir and Dr Coriat have acted as paid consultants for Roche; Prof Goldwasser has acted as a paid consultant for Amgen. Other authors have no conflict of interest to declare.
Authorship: All authors had access to the data and a role in writing the manuscript.